^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ISB 1302

    i
    Other names: ISB 1302, GBR 1302, HBM9302
    Associations

    News

    Trials
    Company:
    Glenmark, Harbour BioMed
    Drug class:
    HER2 inhibitor, CD3 agonist
    Related drugs:
    Associations

    News

    Trials
    over3years
    Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov)
    P1/2, N=1, Terminated, Ichnos Sciences SA | N=158 --> 1 | Trial completion date: Jan 2022 --> Jul 2020 | Recruiting --> Terminated | Trial primary completion date: Aug 2021 --> Jul 2020; The study was terminated during Part 1 (dose escalation), and Part 2 (expansion) of the study was not initiated. This study was voluntarily terminated due to a business decision not to proceed with the ISB 1302 asset, and not due to any safety issue.
    Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • IL7R (Interleukin 7 Receptor) • IL10 (Interleukin 10)
    |
    HER-2 positive
    |
    ISB 1302
    almost5years
    Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov)
    P1/2, N=158, Recruiting, Ichnos Sciences SA | Initiation date: Aug 2019 --> Jan 2020
    Clinical • Trial initiation date • Tumor Mutational Burden
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • IL7R (Interleukin 7 Receptor) • IL10 (Interleukin 10)
    |
    HER-2 positive
    |
    ISB 1302
    5years
    GBR 1302-101: Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers (clinicaltrials.gov)
    P1, N=36, Terminated, Glenmark Pharmaceuticals S.A. | Completed --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
    Clinical • Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    ISB 1302
    5years
    GBR 1302-101: Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers (clinicaltrials.gov)
    P1, N=36, Completed, Glenmark Pharmaceuticals S.A. | Terminated --> Completed | N=60 --> 36
    Clinical • Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    ISB 1302